SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
CIA-Linked Investor Helped Quantum Systems Expand in US 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
OpenAI Rejects Apple Trade Secret Theft Claims 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Add as a preferred source on Google
Dublin, March 16, 2018 -- The "Global Smoking Cessation Partnering 2012 to 2018" report has been added to ResearchAndMarkets.com's offering.
The Global Smoking Cessation Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.
The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
Executive Summary
Chapter 1 - Therapy Partnering trends in numbers
Partnering in numbers - by year
Partnering in numbers - most active
Partnering in numbers - by industry sector
Partnering in numbers - by deal type
Partnering in numbers - by technology type
Partnering in numbers - by stage of development
Chapter 2 - Most active dealmakers
Chapter 3 - Partnering deals directory
Partnering deals directory - by company A-Z
Partnering deals directory - by deal value
Partnering deals directory - by industry sector
Partnering deals directory - by deal type
Partnering deals directory - by stage of development
Partnering deals directory - by technology area
Chapter 4 - Partnering deals with a contract document
Chapter 5 - M&A in numbers
M&A in numbers - by year
Chapter 6 - M&A deals directory
M&A deals directory - by company A-Z
M&A deals directory - by deal value
Chapter 7 - Financing in numbers
Financing in numbers - by year
Financing in numbers - by financing type
Chapter 8 - Financing deals directory
Financing deals directory - by company A-Z
Financing deals directory - by deal value
Financing deals directory - by financing type
For more information about this report visit https://www.researchandmarkets.com/research/c742cq/global_smoking?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Over the Counter (OTC) Drugs
